These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 9155050)

  • 1. MDM2 gene amplification and expression in non-small-cell lung cancer: immunohistochemical expression of its protein is a favourable prognostic marker in patients without p53 protein accumulation.
    Higashiyama M; Doi O; Kodama K; Yokouchi H; Kasugai T; Ishiguro S; Takami K; Nakayama T; Nishisho I
    Br J Cancer; 1997; 75(9):1302-8. PubMed ID: 9155050
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MDM2 mRNA expression is a favorable prognostic factor in non-small-cell lung cancer.
    Ko JL; Cheng YW; Chang SL; Su JM; Chen CY; Lee H
    Int J Cancer; 2000 May; 89(3):265-70. PubMed ID: 10861503
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MDM2 gene amplification: a new independent factor of adverse prognosis in non-small cell lung cancer (NSCLC).
    Dworakowska D; Jassem E; Jassem J; Peters B; Dziadziuszko R; Zylicz M; Jakóbkiewicz-Banecka J; Kobierska-Gulida G; Szymanowska A; Skokowski J; Roessner A; Schneider-Stock R
    Lung Cancer; 2004 Mar; 43(3):285-95. PubMed ID: 15165086
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The expression of murine double minute 2 is a favorable prognostic marker in esophageal squamous cell carcinoma without p53 protein accumulation.
    Saito H; Tsujitani S; Oka S; Ikeguchi M; Maeta M; Kaibara N
    Ann Surg Oncol; 2002 Jun; 9(5):450-6. PubMed ID: 12052755
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alterations of the p16-pRb pathway and the chromosome locus 9p21-22 in non-small-cell lung carcinomas: relationship with p53 and MDM2 protein expression.
    Gorgoulis VG; Zacharatos P; Kotsinas A; Liloglou T; Kyroudi A; Veslemes M; Rassidakis A; Halazonetis TD; Field JK; Kittas C
    Am J Pathol; 1998 Dec; 153(6):1749-65. PubMed ID: 9846966
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular abnormalities of p53, MDM2, and H-ras in synovial sarcoma.
    Oda Y; Sakamoto A; Satio T; Kawauchi S; Iwamoto Y; Tsuneyoshi M
    Mod Pathol; 2000 Sep; 13(9):994-1004. PubMed ID: 11007040
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Heterogeneous distribution of P53 immunoreactivity in human lung adenocarcinoma correlates with MDM2 protein expression, rather than with P53 gene mutation.
    Koga T; Hashimoto S; Sugio K; Yoshino I; Nakagawa K; Yonemitsu Y; Sugimachi K; Sueishi K
    Int J Cancer; 2001 Jul; 95(4):232-9. PubMed ID: 11400116
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MDM2 expression is associated with progress of disease and WAF1 expression in resected lung cancer.
    Aikawa H; Sato M; Fujimura S; Takahashi H; Endo C; Sakurada A; Chen Y; Kondo T; Tanita T; Matsumura Y; Saito Y; Sagawa M
    Int J Mol Med; 2000 Jun; 5(6):631-3. PubMed ID: 10812014
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Wild-type p53 overexpression and its correlation with MDM2 and p14ARF alterations: an alternative pathway to non-small-cell lung cancer.
    Wang YC; Lin RK; Tan YH; Chen JT; Chen CY; Wang YC
    J Clin Oncol; 2005 Jan; 23(1):154-64. PubMed ID: 15625370
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Using whole genome amplification (WGA) of low-volume biopsies to assess the prognostic role of EGFR, KRAS, p53, and CMET mutations in advanced-stage non-small cell lung cancer (NSCLC).
    Lim EH; Zhang SL; Li JL; Yap WS; Howe TC; Tan BP; Lee YS; Wong D; Khoo KL; Seto KY; Tan L; Agasthian T; Koong HN; Tam J; Tan C; Caleb M; Chang A; Ng A; Tan P
    J Thorac Oncol; 2009 Jan; 4(1):12-21. PubMed ID: 19096301
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Altered retinoblastoma protein expression in nonsmall cell lung cancer: its synergistic effects with altered ras and p53 protein status on prognosis.
    Dosaka-Akita H; Hu SX; Fujino M; Harada M; Kinoshita I; Xu HJ; Kuzumaki N; Kawakami Y; Benedict WF
    Cancer; 1997 Apr; 79(7):1329-37. PubMed ID: 9083154
    [TBL] [Abstract][Full Text] [Related]  

  • 12. mdm2 gene amplification and overexpression in non-small cell lung carcinomas with accumulation of the p53 protein in the absence of p53 gene mutations.
    Marchetti A; Buttitta F; Pellegrini S; Merlo G; Chella A; Angeletti CA; Bevilacqua G
    Diagn Mol Pathol; 1995 Jun; 4(2):93-7. PubMed ID: 7551299
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Amplification of the MDM2 gene in human breast cancer and its association with MDM2 and p53 protein status.
    McCann AH; Kirley A; Carney DN; Corbally N; Magee HM; Keating G; Dervan PA
    Br J Cancer; 1995 May; 71(5):981-5. PubMed ID: 7734324
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic value of the apoptotic index analysed jointly with selected cell cycle regulators and proliferation markers in non-small cell lung cancer.
    Dworakowska D; Jassem E; Jassem J; Karmoliński A; Lapiński M; Tomaszewski D; Rzyman W; Jaśkiewicz K; Sworczak K; Grossman AB
    Lung Cancer; 2009 Oct; 66(1):127-33. PubMed ID: 19200616
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Associations of MDM2 SNP309, transcriptional activity, mRNA expression, and survival in stage I non-small-cell lung cancer patients with wild-type p53 tumors.
    Chien WP; Wong RH; Cheng YW; Chen CY; Lee H
    Ann Surg Oncol; 2010 Apr; 17(4):1194-202. PubMed ID: 19941079
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Altered expression of the cell cycle regulatory molecules pRb, p53 and MDM2 exert a synergetic effect on tumor growth and chromosomal instability in non-small cell lung carcinomas (NSCLCs).
    Gorgoulis VG; Zacharatos P; Kotsinas A; Mariatos G; Liloglou T; Vogiatzi T; Foukas P; Rassidakis G; Garinis G; Ioannides T; Zoumpourlis V; Bramis J; Michail PO; Asimacopoulos PJ; Field JK; Kittas C
    Mol Med; 2000 Mar; 6(3):208-37. PubMed ID: 10965496
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical significance of apoptotic index in non-small cell lung cancer: correlation with p53, mdm2, pRb and p21WAF1/CIP1 protein expression.
    Dworakowska D; Jassem E; Jassem J; Karmoliński A; Dworakowski R; Wirth T; Gruchała M; Rynkiewicz A; Skokowski J; Yla-Herttuala S; Jaśkiewicz K; Czestochowska E
    J Cancer Res Clin Oncol; 2005 Sep; 131(9):617-23. PubMed ID: 16028106
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MDM2/p53 co-expression in oral premalignant and malignant lesions: potential prognostic implications.
    Agarwal S; Mathur M; Srivastava A; Ralhan R
    Oral Oncol; 1999 Mar; 35(2):209-16. PubMed ID: 10435158
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synergistic activation of p53 by inhibition of MDM2 expression and DNA damage.
    Chen L; Agrawal S; Zhou W; Zhang R; Chen J
    Proc Natl Acad Sci U S A; 1998 Jan; 95(1):195-200. PubMed ID: 9419352
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of p53 oncoprotein in non-small-cell lung cancer: a favorable prognostic factor.
    Lee JS; Yoon A; Kalapurakal SK; Ro JY; Lee JJ; Tu N; Hittelman WN; Hong WK
    J Clin Oncol; 1995 Aug; 13(8):1893-903. PubMed ID: 7636531
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.